Traced to FDA primary documents
FDA Peptide Status Tracker
The FDA compounding status of every substance PEPLUX tracks. Each status traces to named, dated FDA documents rather than to a summary of them. Where FDA has not yet published an advisory committee outcome, the record names the secondary report it relies on. Records were last checked between October 13, 2026 and October 14, 2026; each row shows its own date.
Read this first
Removal from FDA Category 2 is not FDA approval.
Removal from FDA's Category 2 is not FDA approval and not a listing. FDA removed several peptides from its 503A Category 2 after their nominators withdrew the nominations, not because the substances were found safe: BPC-157, TB-500, MOTS-c, semax and epitalon among others (removal noticed April 15, 2026, effective after 7 days), and CJC-1295 and ipamorelin earlier (removal notice dated September 27, 2024). None was added to the 503A bulks list, so none has a compounding pathway today. A favorable vote by FDA's Pharmacy Compounding Advisory Committee is a recommendation, not a listing: nothing changes unless FDA publishes a final rule.
An FDA advisory committee recommendation is not a listing. Nothing changes unless FDA publishes a final rule.
The full list
Every substance we track, by FDA status.
Grouped by FDA status, then sorted alphabetically. Select any substance for the full record, the documents it traces to and the date it was last checked.
Scroll the table sideways to see every column.
| Substance | FDA status | Compounding basis | Advisory committee | WADA 2026 | Offered | Checked on |
|---|---|---|---|---|---|---|
| FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | ||||||
| Enclomiphene CitrateEnclomiphene | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy) | Not reviewed | S4.2 | No | |
| GHK-CuCopper tripeptide-1, Copper peptide GHK-Cu | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy)Injectable routes (subcutaneous, intramuscular and intravenous): No compounding pathway today. | Review announced, expected by Feb 28, 2027 | Not named | YesGHK-Cu Injection | |
| GlutathioneL-glutathione | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy)503B outsourcing facility (Category 1, interim policy) | Not reviewed | Not named | YesGlutathione | |
| MethylcobalaminMethyl B12, Mecobalamin | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy)503B outsourcing facility (Category 1, interim policy) | Not reviewed | Not named | YesMethylcobalamin B12 | |
| Nicotinamide Adenine Dinucleotide (NAD)NAD+, NAD, Nicotinamide adenine dinucleotide | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy)503B outsourcing facility (Category 1, interim policy) | Not reviewed | Not named | YesNAD+ | |
| Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH)NADH, Reduced nicotinamide adenine dinucleotide | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy) | Not reviewed | Not named | No | |
| Sermorelin AcetateSermorelin | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503B outsourcing facility (Category 1, interim policy) | Not reviewed | S2.2.4 | YesSermorelin | |
| Vasoactive Intestinal PeptideVIP, Aviptadil | FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. | 503A pharmacy (Category 1, interim policy) | Not reviewed | Not named | No | |
| Narrow compounding pathway, limited by the rule on copies of approved drugs. Compounded versions are not FDA-approved. | ||||||
| Bremelanotide (PT-141)PT-141, Bremelanotide | Narrow compounding pathway, limited by the rule on copies of approved drugs. Compounded versions are not FDA-approved. | 503A pharmacy (component of an approved drug) | Not reviewed | Not named | YesPT-141 | |
| No compounding pathway today. An FDA advisory committee recommendation is not a listing. | ||||||
| BPC-157Body Protection Compound-157 | No compounding pathway today. An FDA advisory committee recommendation is not a listing. | No compounding pathway | Recommended, not added, Jul 23, 2026 | S0 | YesBPC-157 Injection | |
| EpitalonEpithalon | No compounding pathway today. An FDA advisory committee recommendation is not a listing. | No compounding pathway | Recommended, not added, Jul 24, 2026 | Not named | YesEpitalon | |
| KPVLys-Pro-Val | No compounding pathway today. An FDA advisory committee recommendation is not a listing. | No compounding pathway | Recommended, not added, Jul 23, 2026 | Not named | YesKLOW Stack | |
| MOTS-cMOTs-C | No compounding pathway today. An FDA advisory committee recommendation is not a listing. | No compounding pathway | Recommended, not added, Jul 23, 2026 | S4.4.1 | YesMOTS-c | |
| Semax (heptapeptide)Semax | No compounding pathway today. An FDA advisory committee recommendation is not a listing. | No compounding pathway | Recommended, not added, Jul 24, 2026 | Not named | YesSemax | |
| Thymosin beta-4, fragment (LKKTETQ)TB-500 | No compounding pathway today. An FDA advisory committee recommendation is not a listing. | No compounding pathway | Recommended, not added, Jul 23, 2026 | S2.3 | YesWolverine Stack | |
| No compounding pathway today. | ||||||
| AOD-9604 | No compounding pathway today. | No compounding pathway | Voted against, Dec 4, 2024 | S2.2.3 | YesAOD-9604 | |
| CJC-1295 | No compounding pathway today. | No compounding pathway | Voted against, Dec 4, 2024 | S2.2.4 | YesCJC-1295 and Ipamorelin | |
| Emideltide (DSIP)DSIP, Delta sleep-inducing peptide | No compounding pathway today. | No compounding pathway | Not recommended, Jul 24, 2026 | Not named | YesDSIP Injection | |
| Ipamorelin acetateIpamorelin | No compounding pathway today. | No compounding pathway | Voted against, Oct 29, 2024 | S2.2.4 | YesCJC-1295 and Ipamorelin | |
| Kisspeptin-10Kisspeptin, KP-10 | No compounding pathway today. | No compounding pathway | Voted against, Oct 29, 2024 | S2.2.1 (males) | YesKisspeptin Injection | |
| Retatrutide | No compounding pathway today. | No compounding pathway | Not reviewed | S0 | No | |
| Selank acetate (TP-7)Selank, TP-7 | No compounding pathway today. | No compounding pathway | Not reviewed | Not named | YesSelank | |
| Thymosin beta-4 (full-length) | No compounding pathway today. | No compounding pathway | Not reviewed | S2.3 | No | |
| Cannot be compounded. | ||||||
| Tesamorelin | Cannot be compounded. | Branded product only | Not reviewed | S2.2.4 | No | |
“Offered” means a PEPLUX product contains the substance. It says nothing about FDA approval, and it is not a recommendation to use any substance on this page.
Methodology
Where each status comes from.
Two FDA documents carry most of the weight, and confusing them is the source of most published errors. The 503A document governs state-licensed pharmacies compounding against patient-specific prescriptions. The 503B document governs outsourcing facilities registered with FDA. A substance can appear in one and not the other.
- FDA 503A categoriesBulk drug substances nominated for use in compounding under section 503A (categories), updated May 14, 2026Document dated . Checked .
- FDA 503B categoriesBulk drug substances nominated for use in compounding under section 503B (categories), updated March 21, 2025Document dated . Checked .
What we do not use as a source
- Vendor and telehealth marketing pages, which often conflate the 503A and 503B documents.
- Content-farm summaries and automated status roundups that repeat those errors.
- Supplier and research-chemical listings. That a substance can be bought says nothing about whether it can be compounded.
- Anything we cannot trace to a dated document. Where a fact is not confirmed, or rests on a secondary report because FDA has not published it, the record says so.
Each record carries the date it was last checked. If a date looks old to you, treat that record as possibly out of date.
Common questions
The questions this tracker exists to answer.
- Does removal from FDA Category 2 mean FDA has approved a peptide, or that it can be compounded?
- Removal from FDA's Category 2 is not FDA approval and not a listing. FDA removed several peptides from its 503A Category 2 after their nominators withdrew the nominations, not because the substances were found safe: BPC-157, TB-500, MOTS-c, semax and epitalon among others (removal noticed April 15, 2026, effective after 7 days), and CJC-1295 and ipamorelin earlier (removal notice dated September 27, 2024). None was added to the 503A bulks list, so none has a compounding pathway today. A favorable vote by FDA's Pharmacy Compounding Advisory Committee is a recommendation, not a listing: nothing changes unless FDA publishes a final rule.
- How is each substance on this tracker grouped?
- Enclomiphene Citrate, GHK-Cu, Glutathione, Methylcobalamin, Nicotinamide Adenine Dinucleotide (NAD), Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH), Sermorelin Acetate, Vasoactive Intestinal Peptide: FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved. Bremelanotide (PT-141): Narrow compounding pathway, limited by the rule on copies of approved drugs. Compounded versions are not FDA-approved. BPC-157, Epitalon, KPV, MOTS-c, Semax (heptapeptide), Thymosin beta-4, fragment (LKKTETQ): No compounding pathway today. An FDA advisory committee recommendation is not a listing. AOD-9604, CJC-1295, Emideltide (DSIP), Ipamorelin acetate, Kisspeptin-10, Retatrutide, Selank acetate (TP-7), Thymosin beta-4 (full-length): No compounding pathway today. Tesamorelin: Cannot be compounded.
- Which of these substances does PEPLUX offer?
- PEPLUX offers Sermorelin, which contains Sermorelin Acetate; NAD+, which contains Nicotinamide Adenine Dinucleotide (NAD); Glutathione, which contains Glutathione; Methylcobalamin B12, which contains Methylcobalamin; CJC-1295 and Ipamorelin, which contains CJC-1295 and Ipamorelin acetate; MOTS-c, which contains MOTS-c; BPC-157 Injection, which contains BPC-157; Epitalon, which contains Epitalon; Semax, which contains Semax (heptapeptide); Selank, which contains Selank acetate (TP-7); AOD-9604, which contains AOD-9604; PT-141, which contains Bremelanotide (PT-141); GHK-Cu Injection, which contains GHK-Cu; BPC-157 Capsules, which contains BPC-157; Topical GHK-Cu, which contains GHK-Cu; Wolverine Stack, which contains BPC-157 and Thymosin beta-4, fragment (LKKTETQ); GLOW Stack, which contains BPC-157 and GHK-Cu and Thymosin beta-4, fragment (LKKTETQ); KLOW Stack, which contains BPC-157 and GHK-Cu and KPV and Thymosin beta-4, fragment (LKKTETQ); Semax / Selank Injection, which contains Semax (heptapeptide) and Selank acetate (TP-7); Kisspeptin Injection, which contains Kisspeptin-10; DSIP Injection, which contains Emideltide (DSIP). Every other substance on this tracker is not offered. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.
- Where does this tracker get its data?
- Each status traces to dated primary documents: FDA's 503A and 503B category documents, the Federal Register, the eCFR, approved drug labels and FDA advisory committee records. Each record shows the date printed on every document and the date it was last checked. Where FDA has not yet published the outcome of an advisory committee meeting, a record may report that outcome from a named secondary report, and the record says so. Vendor and content-farm sites are never used as sources.